1 Occurrence of immediate adverse events within two hours of vaccination <br/ >2 Occurrence of solicited local and systemic adverse events within 7 days after vaccination and unsolicited adverse events within 28 days after vaccination. <br/ >3 Occurrence of Serious Adverse Events throughout the study duration. <br/ >4 Occurrence of Adverse Events of Special Interest (AESI) throughout the study duration <br/ >5 To evaluate the GMTs and seroconversion of COVAXIN®Timepoint: Day 28±2; 56±7; 118±7 and 208±7

1 Occurrence of immediate adverse events within two hours of vaccination <br/ >2 Occurrence of solicited local and systemic adverse events within 7 days after vaccination and unsolicited adverse events within 28 days after vaccination. <br/ >3 Occurrence of Serious Adverse Events throughout the study duration. <br/ >4 Occurrence of Adverse Events of Special Interest (AESI) throughout the study duration <br/ >5 To evaluate the GMTs and seroconversion of COVAXIN®Timepoint: Day 28±2; 56±7; 118±7 and 208±7

N/A

N/A

1 Occurrence of immediate adverse events within two hours of vaccination <br/ >2 Occurrence of solicited local and systemic adverse events within 7 days after vaccination and unsolicited adverse events within 28 days after vaccination. <br/ >3 Occurrence of Serious Adverse Events throughout the study duration. <br/ >4 Occurrence of Adverse Events of Special Interest (AESI) throughout the study duration <br/ >5 To evaluate the GMTs and seroconversion of COVAXIN®Timepoint: Day 28±2; 56±7; 118±7 and 208±7

1 Occurrence of immediate adverse events within two hours of vaccination <br/ >2 Occurrence of solicited local and systemic adverse events within 7 days after vaccination and unsolicited adverse events within 28 days after vaccination. <br/ >3 Occurrence of Serious Adverse Events throughout the study duration. <br/ >4 Occurrence of Adverse Events of Special Interest (AESI) throughout the study duration <br/ >5 To evaluate the GMTs and seroconversion of COVAXIN®Timepoint: Day 28±2; 56±7; 118±7 and 208±7